Replies to post #158268 on Biotech Values

[bladerunner1717]

re: GERN CC

One analyst,God bless him, wanted to know how "Chip" could justify his $900,000 compensation or how the company could justify not running any company-sponsored trials. Chip's answers were rather lame, I thought. And the analyst kept hammering away at him. Toughest questioning I've ever heard on a small-cap biotech CC. It sounded like BTH was on the call. LOLOL

This is turning out to be a very bad investment for me.

And what exactly are they spending $33 million/year on, when they have no company-sponsored trials to run.


Bladerunner

[jq1234]

I just read the cc transcript. I'd agree stopping PV enrollment with 2 patients doesn't make any sense. I can understand they don't want to enroll any more ET patients.

They also have been trying different dosing schedules in different trials, ET/PV weekly, MM twice every 4 weeks, NSCLC twice every 3 weeks, IST MF once every 3 weeks. I don't know whether this was due to concern of overall safety of imetelstat or due to different indications. They are trying too hard to me. It doesn't make sense dosing less frequently in MF than in ET/PV unless they gave up induction/maintenance in MF like they did in ET/PV. Maybe they just don't know at this point. Like they said, ET was big surprise, and they don't have that much expertise in hematology yet, wanted to be cautious with how to move forward. That's the only thing I can think of as positive at the moment if it IS the reason they are not doing much themselves this year.